Please help with biopsy results

september18
september18 Member Posts: 10

Overwhelmed and scared.

====

A. Right breast, R1 at 10:00, 3 cm from nipple, core biopsy 

  • Invasive ductal carcinoma (see comments) 
  • Focal ductal carcinoma in situ

B. Right axilla, rax at 10:00, 10-11 cm from nipple, core biopsy 

  • One lymph node, negative for carcinoma (0/1) 

Value

INVASIVE CARCINOMA OF THE BREAST: Biopsy

INVASIVE CARCINOMA OF THE BREAST: BIOPSY - All Specimens

SPECIMEN

   Procedure:    Needle biopsy 

   Specimen Laterality:    Right 

TUMOR

   Histologic Type:    Invasive carcinoma of no special type (ductal) 

   Histologic Grade (Nottingham Histologic Score):    

     Glandular (Acinar) / Tubular Differentiation:    Score 3 

     Nuclear Pleomorphism:    Score 2 

     Mitotic Rate:    Score 1 

     Overall Grade:    Grade 2 (scores of 6 or 7) 

   Largest Invasive Focus in this Limited Biopsy Sample:    9.9 mm

   Ductal Carcinoma In Situ (DCIS):    Not identified 

   Lymphatic and / or Vascular Invasion:    Not identified 

   Microcalcifications:    Not identified 

Breast Biomarker Reporting Template

BREAST BIOMARKER REPORTING TEMPLATE - All Specimens

Test(s) Performed:    

     Estrogen Receptor (ER) Status:    Positive (greater than 10% of cells demonstrate nuclear positivity) 

       Percentage of Cells with Nuclear Positivity:    91-100% 

       Average Intensity of Staining:    Strong 

     Test Type:    Food and Drug Administration (FDA) cleared (test / vendor): Ventana Roche 

     Primary Antibody:    SP1 

   Test(s) Performed:    

     Progesterone Receptor (PgR) Status:    Positive 

       Percentage of Cells with Nuclear Positivity:    91-100% 

       Average Intensity of Staining:    Strong 

     Test Type:    Laboratory-developed test 

     Primary Antibody:    1E2 

   Test(s) Performed:    

     HER2 by Immunohistochemistry:    Negative (Score 1+) 

     Test Type:    Food and Drug Administration (FDA) cleared (test / vendor): Ventana Roche 

     Primary Antibody:    4B5 

   Test(s) Performed:  

     HER2 by in situ Hybridization:    Negative (not amplified) 

     Method:    Dual probe assay 

       Average Number of HER2 Signals per Cell:    1.9 

       Average Number of CEP17 Signals per Cell:    1.55

       HER2 / CEP17 Ratio:    1.23 

     Test Type:    Food and Drug Administration (FDA) cleared (test / vendor): Ventana HER2 Dual ISH DNA Probe Cocktail 

   Test(s) Performed:    Ki-67 

     Ki-67 Percentage of Positive Nuclei:    20 %

     Primary Antibody:    MIB1 

   Cold Ischemia and Fixation Times:    Meet requirements specified in latest version of the ASCO / CAP Guidelines 

   Testing Performed on Block Number(s):    A1 

METHODS

   Fixative:    Formalin 

   Image Analysis:    Not performed 

   Comment(s):    HER2 IHC was scored and reported according to ASCO/CAP Guidelines as negative, equivocal or positive for protein overexpression. As of 6/2024, in order to identify all cancers that may be eligible for evolving treatments targeting minimal levels of HER2 expression, samples reported as IHC 0 here exclude cases with any membranous staining (even if <10% of the sample). Samples with a reported score of IHC 1+ include all cases that have any incomplete membranous staining (both >10% and <10% of the sample).